The most precise estimates of IRIS occurrence range from 25%–32.5%, developing on average 8 weeks after the initiation of HAART, with increased expression of pro-inflammatory markers including IFNγ, TNFα, and eotaxin in CM-IRIS patients as compared to individuals simply experiencing a relapse of CM [151,152]. The gene discussed is CCL11; the disease is cutaneous mastocytosis.